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Abstract Carcinoma of unknown primary (CUP) is a
heterogeneous group of metastatic malignancies in which
a primary tumor could not be detected despite thorough
diagnostic evaluation. Because of its high sensitivity for the
detection of lesions, combined
18F-fluoro-2-deoxyglucose
positron emission tomography (FDG PET)/computed to-
mography (CT) may be an excellent alternative to CT alone
and conventional magnetic resonance imaging in detecting
the unknown primary tumor. This article will review the
use, diagnostic performance, and utility of FDG PET/CT in
CUP and will discuss challenges and future considerations
in the diagnostic management of CUP.
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Introduction
Carcinoma of unknown primary (CUP) is defined as a
biopsy-proven malignancy whose anatomical origin
remains unidentified after a thorough diagnostic evaluation.
Such an evaluation should have included a detailed medical
history, complete physical examination including pelvic
and rectal examination, full blood count and biochemistry,
urinalysis and stool occult blood testing, histopathological
review of biopsy material with the use of immunohisto-
chemistry, chest radiography, computed tomography (CT)
of the abdomen and pelvis, and, in certain cases, mam-
mography [1]. CUP is the seventh to eighth most frequently
occurring cancer in the world and the fourth commonest
cause of cancer-related death in both men and women [1].
CUP accounts for approximately 2.3–4.2% of cancer in
both sexes. The annual age-adjusted incidence per 100,000
population in the USA is 7–12 cases, in Australia 18–19
cases, and in the Netherlands 5.3–6.7 cases [1]. Obviously,
the definition of CUP is arbitrary, and the development and
application of more sophisticated diagnostic tests will
decrease the incidence and prevalence of CUP. Patients
with CUP are categorized into favorable and unfavorable
subsets, according to number, location(s), and histology of
metastases. Some favorable subsets require specific treat-
ment approaches and have the potential for an excellent
outcome [1]. However, in general, CUP follows an
aggressive biological and clinical behavior, with a median
survival ranging from only 2 to 10 months [1]. Neverthe-
less, it can be hypothesized that detection of a primary
tumor may optimize treatment planning, which, in turn,
may improve patient outcome. Indeed, some studies have
shown that survival in patients in whom a primary tumor
was eventually detected was higher than in patients in
whom the primary tumor remained undetected [2, 3].
Additional diagnostic procedures that can be used for
primary tumor detection include a combination of various
radiological, endoscopic, and serum tumor marker studies,
depending on the specific signs and symptoms, histological
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DOI 10.1007/s00259-009-1295-6results, and laboratory abnormalities [1]. However, these
tests can be expensive, time-consuming, and invasive.
Furthermore, in the majority of patients these tests may
eventually fail to detect a primary tumor. Clearly, there is a
need for an alternative, noninvasive imaging modality with
a high diagnostic yield. In this context, combined positron
emission tomography (PET)/CT, using the radiotracer
18F-
fluoro-2-deoxyglucose (FDG) may be an excellent
problem-solving tool in patients with CUP. This article will
review the use, diagnostic performance, and utility of FDG
PET/CT in CUP and will discuss challenges and future
considerations in the diagnostic management of CUP.
FDG PET/CT in CUP
Why?
CT and magnetic resonance imaging (MRI) are two of the
main technologies that came to dominate imaging of human
disease in clinical practice. Major advantages of these
techniques are their ability to provide cross-sectional
images of the entire body, which is especially important
in CUP, because the primary tumor can be located
anywhere in the body. In addition, whole-body imaging
may detect or exclude additional metastatic sites, which
may have important therapeutic or prognostic consequen-
ces. However, CT and conventional MRI including (con-
trast-enhanced) T1-weighted and T2-weighted sequences
are limited in that they basically only allow for the
detection of anatomical abnormalities and abnormal con-
trast enhancement, as a result of which small lesions and
non-enhancing lesions in normal-sized structures may be
missed. This may in particular be an issue in CUP, in which
the primary tumor may be of small size [1]. In addition,
functional or metabolic pathological changes can occur in
the absence of any corresponding anatomical changes and
are not visualized by anatomical imaging at all. Further-
more, large amounts of image data are obtained in a single
whole-body CT or MRI examination, as a result of which
image interpretation is complex, time-consuming, and
subtle pathological findings may be overlooked. Therefore,
sensitivity of CT and anatomical MRI for the detection of
the unknown primary tumor may be compromised. FDG
PET does not have these drawbacks and may be an
excellent alternative whole-body imaging modality in
patients with CUP, as was already reported by Rege et al.
[4] in 1994. The rationale for the use of the radiotracer
FDG for PET imaging in CUP is the fact that the vast
majority of malignant cancer phenotypes exhibit an
increased glucose metabolism (Warburg effect) [5]. In
contrast to CT and conventional MRI, FDG PET offers
high lesion-to-background contrast, making it a potentially
more sensitive imaging modality for the detection of
lesions. For example, Roh et al. [6] have shown that
sensitivity of FDG PET/CT (87.5%) was significantly
higher (p=0.016) than that of CT alone (43.7%) in
detecting primary tumors in 44 patients presenting with
cervical metastases from unknown origin. Similarly, in the
study by Nassenstein et al. [7] who investigated 39 patients
with cervical metastases of unknown origin CT alone
revealed the primary tumor in only 5 patients (13%), while
FDG PET alone and combined FDG PET/CT detected a
primary tumor in 10 patients (26%) and 11 patients (28%),
respectively. In addition, in their series of 21 patients with
cervical metastases of unknown origin, Freudenberg et al.
[8] showed that CT alone detected only 5 primary tumors
(23%), while FDG PET alone and combined FDG PET/CT
detected 11 primary tumors (52%) and 12 (57%) primary
tumors, respectively, with a significant difference (p=0.03)
between CT alone and FDG PET/CT. Furthermore, Gutzeit
et al. [9] reported that CT alone depicted a primary tumor in
only 8 of 45 patients (18%), while FDG PET alone and
combined FDG PET/CT detected primary tumors in 11
patients (24%) and 15 patients (33%), respectively. Current
commercially available PET systems can now reach a
spatial resolution of about 4–7 mm for whole-body imaging
[5, 10], but thanks to its high lesion-to-background contrast,
lesions with a size below this spatial resolution may even
be detectable.
How to perform?
In the majority of clinics combined PET/CT systems,
equipped with 16- to 64-section multidetector row CT
units, have replaced the stand-alone PET scanner [10]. The
CT component of a combined PET/CT system offers well-
recognized advantages, such as more accurate localization
of sites with FDG uptake, thereby reducing the problems of
physiological FDG uptake being misinterpreted as patho-
logical and false localization of disease and allowing for
more accurate image-guided biopsy of suspected primary
tumor sites. Furthermore, its use for attenuation correc-
tion of PET emission data provides low-noise attenuation
correction factors, eliminates bias from emission con-
tamination of postinjection transmission scans, and
reduces whole-body FDG PET/CT examinations to 10
min or less [10]. Three studies [7–9] have directly
compared FDG PET/CT to (CT-based attenuation-
corrected) FDG PET alone in CUP. In all three studies
[7–9], FDG PET/CT was able to detect a few more
primary tumors than FDG PET alone, although these
differences were not statistically significant. Nevertheless,
a combined PET/CTsystem is favored above a stand-alone
PET scanner in patients with CUP because of its
previously mentioned advantages.
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patients with CUP, a standard protocol can be used [11].
Importantly, although the optimal time for data acquisition
has not been determined yet in CUP, it may be recom-
mended to perform (additional) delayed PET imaging (e.g.,
3 or 4 h after FDG administration) in order to improve
lesion-to-background contrast, as will be discussed in a
later section. As will be outlined in a later section, the lung
has been reported to represent one of the two main
locations with the highest number of false-positive FDG
PET/CT results in patients with CUP [12]. It has also been
reported that focal intrapulmonary FDG uptake may occur
as a result of iatrogenic pulmonary microembolism due to
aspiration of blood during intravenous FDG administration
[13], which should be avoided. The second main location of
false-positive FDG PET/CT results is the oropharynx [12].
Although the risk of physiological FDG uptake being
misinterpreted as a lesion cannot be completely eliminated,
patients should be instructed to avoid or minimize talking,
chewing, and swallowing immediately before and after
FDG administration in order to minimize FDG uptake in
the laryngeal and pharyngeal muscles [14].
Although data regarding the influence of different CT
protocols on diagnostic performance of FDG PET/CTin CUP
are largely lacking, it is recommended to use a collimation of
lessthan2.5mm,inordertodetectsmallprimarylungcancers
[15]. Of note, lung cancer is the most frequently reported
primary tumor in patients with CUP [12, 16–19]. While it
may be argued that the use of intravenous and oral contrast
agents may improve detectability of the primary tumor,
neither the study of Fencl et al. [20]n o rar e c e n tm e t a -
analysis [12] showed any beneficial effect of this approach
on diagnostic performance in patients with CUP compared to
using no contrast agents at all. Furthermore, because regions
containing high concentrations of contrast medium may
artificially lead to overestimation of FDG uptake when using
CT-based attenuation correction [21], and because iodinated
contrast agents may cause adverse reactions, including rarely
occurring but life-threatening contrast-induced nephrotoxici-
ty and anaphylactic shock [22], it may be preferred to
perform a CT scan without contrast agents.
How to interpret?
The most frequently reported unknown primary tumor
locations include the lung, pancreas, and oropharynx [12,
16–19]. Therefore, these locations should carefully be
evaluated. Furthermore, histopathological diagnosis and
metastatic pattern may suggest possible locations of the
primary tumor. For example, in patients with involvement
of the upper or mid-cervical lymph nodes, a primary site in
the head and neck should be suspected [23]. In patients
with poorly differentiated carcinoma and left supraclavicu-
lar lymphadenopathy (Virchow’s node), a primary gastro-
intestinal tumor may be detected [23]. In women with
axillary lymph node metastases, primary breast cancer may
be suspected. On the other hand, women with peritoneal
carcinomatosis may have primary ovarian cancer [23].
Furthermore, in men with osteoblastic bone metastases,
prostate cancer may be the primary tumor [23]. Nevertheless,
the primary tumor can be located anywhere in the body, and
the entire body should be carefully reviewed for lesions,
including previously undetected additional metastases.
Finally, special attention should be paid to the evaluation
of the oropharynx and lung, because these are the locations
with the most frequently reported false-positive FDG PET/
CT results [12] (Figs. 1 and 2). The oropharynx is a
difficult area to evaluate; physiological FDG uptake in the
lymphoid tissue of the adenoids and Waldeyer’s ring, and
overlap between tumor and physiologic FDG uptake, may
impair diagnostic performance [24]. Nevertheless, accurate
localization of increased FDG uptake using CT images may,
in part, reduce the rate of false-positive results (e.g.,
recognition of physiological muscle FDG uptake). Further-
more, although focally increased FDG uptake may resemble a
primary lung cancer, its CT pattern may indicate the presence
of a benign inflammatory or infectious lesion (e.g., pneumo-
nias usually present with a lobular, segmental, or lobar pattern
onCT),orapulmonaryembolismorinfarction(e.g.,awedge-
shaped peripheral region of consolidation on CTshould raise
the possibility of a pulmonary infarction) [25–27].
Diagnostic yield
It should be realized that despite extensive work-up, less
than 20% of patients with CUP have a primary site of their
cancer identified antemortem. In addition, autopsy studies
have reported that 70% of cases remained undiagnosed [1],
which well reflects the diagnostic challenge of currently
available imaging modalities. It has still not been clarified
why the majority of primary tumors cannot be detected.
Common hypotheses include spontaneous regression or
immune-mediated destruction of the primary tumor or the
inherent small size of the primary tumor (metastatic spread
is favored above local tumor growth) [1, 28, 29].
Several meta-analyses have assessed the diagnostic
performance of stand-alone FDG PET in patients with
CUP [30–32], reporting primary tumor detection rates of
41% [30], 24.5% [31], and 43% [32], with a generally
higher sensitivity than specificity using histopathological
analysis of tissue obtained by biopsy or surgery and/or
other imaging procedures or clinical follow-up as the
standard of reference [30–32]. However, as mentioned
previously, combined PET/CT systems have many advan-
tages over the stand-alone PET scanner and are rapidly
replacing the latter. One recent meta-analysis investigated
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primary tumor detection rate of 37% [12]. Diagnostic
performance of FDG PET/CT was not significantly differ-
ent between patients presenting with cervical metastases
and patients presenting with extracervical metastases, while
lung, oropharyngeal, and pancreatic cancer were reported to
represent the most frequently detected primary tumors
(Fig. 3)[ 12]. Lung and pancreatic cancer are indeed also
the most common primary tumor locations in autopsy
studies [16–19]. The rather unexpected high rate of primary
oropharyngeal cancers in the aforementioned meta-analysis
[12] can be explained by the fact that it included a large
proportion of patients with cervical metastases, whose
primary tumors are most frequently located in the orophar-
ynx [33]. On the other hand, breast cancer appears to be the
most common cause of a false-negative FDG PET/CT result
(Fig. 4)[ 12]. This is due to the well-documented inability
of FDG PET(/CT) to consistently demonstrate small
(<1.0 cm) and low-grade lesions with low or no FDG
uptake (e.g., tubular carcinoma and noninvasive cancers
such as ductal or lobular carcinoma in situ) [34]. This
limitation of FDG PET/CT should be kept in mind and in
case of a high suspicion of a primary breast cancer (e.g., in
case of axillary lymph node metastases) [23], a dedicated
MRI scan may be considered [35, 36]. Similar to that in the
breast, false-negative FDG PET/CTresults in other locations
are most likely attributable to small lesion size and low or no
FDG uptake. In contrast, the oropharynx and the lung are the
two most common locations of false-positive FDG PET/CT
results [12] (Fig. 5). Literature on the exact causes of false-
positive FDG PET/CT results is scarce, although benign
inflammatory lesions [7, 9, 37] and pulmonary infarction
[9] have been reported etiologies. Furthermore, of special
note is the fact that incidental pulmonary emboli have been
reported to occur in 4% of patients with cancer [38]. It can
be speculated that this may, in part, explain the rate of false-
positive FDG PET/CT results in the lung. Figures 1 and 2
show two examples in which FDG PET/CT was able to
detect the unknown primary tumor.
Is it worthwhile?
Although it is widely accepted that CUP is a heterogeneous
group of metastatic malignancies, the true nature of this
Fig. 1 FDG PET/CT in a 52-year-old man who presented with a
pathologically enlarged left cervical lymph node. Excision biopsy of
the lymph node and subsequent histopathological examination
indicated metastatic squamous cell carcinoma of unknown primary.
Microdirect laryngoscopy and bronchoscopy were performed with
(blind) biopsy and tonsillectomy; subsequent histopathological exam-
ination only showed reactive changes in the tonsils, pyriform sinus,
and left tongue base, without any indication for the presence of
primary tumor. FDG PET in the coronal (a) and axial plane (b) shows
intense FDG uptake in the left supraglottic region (arrows), likely
representing the primary tumor. Corresponding CT and fused FDG
PET/CT images in the coronal (b, c, respectively) and axial plane (e, f,
respectively) localize the lesion at the base of the tongue (arrows).
Histopathological examination of a directed biopsy of the lesion
revealed in situ squamous cell carcinoma of the tongue base
(moderately to poorly differentiated)
638 Eur J Nucl Med Mol Imaging (2010) 37:635–644clinical entity is still unknown. CUP may be considered as
metastatic disease in patients in whom the primary tumor
has not been found and which did not result in clinical signs
of disease [28, 29]. If this is the case, detection of the
primary tumor is worthwhile, because it may lead to more
specific treatment planning and improve outcome [28, 29].
On the other hand, CUP may represent a separate group of
cancers with genetic and phenotypic characteristics that
Fig. 2 FDG PET/CT in a 61-year-old woman who presented with a
right neck mass. Neck CT confirmed the pathologically enlarged right
cervical lymph node, showed slight asymmetry at the right tongue
base and oropharynx, and an enlarged, heterogeneous right lobe of the
thyroid gland. Fine-needle biopsy and subsequent histopathological
examination of the pathologically enlarged right cervical lymph node
indicated metastatic carcinoma of unknown primary. Tumor cells were
positive for CK7, focally positive for TFF1, and negative for
calcitonin and thyroglobulin, suggesting the possibility of a primary
lung tumor. FDG PET in the axial (a) and coronal plane (d) shows
intense FDG uptake of the thyroid (arrows), likely representing the
primary tumor, and intense FDG uptake in the right cervical,
supraclavicular, and paratracheal lymph nodes. Corresponding CT
and fused FDG PET/CT images in the axial (b, c, respectively) and
coronal plane (e, f, respectively) confirm the localization of the lesions
seen at FDG PET (arrows). Fine-needle aspiration of the thyroid and
subsequent histopathological examination revealed a primary papillary
thyroid carcinoma
Fig. 3 Bar graph showing
percentages of primary tumors
detected by FDG PET/CT per
location [12]
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case, detection of the primary tumor is of minor impor-
tance, and diagnostic evaluation should focus on the
identification of treatable subsets [28, 29]. In other words,
research should focus on the metastatic genotype and
phenotype and on the detection of specific biochemical or
molecular targets for the development of CUP-specific
therapy [28, 29]. It should also be realized that FDG PET/
CT is an expensive examination, and false-positive FDG
PET/CT findings may result in unnecessary additional
invasive diagnostic procedures, which have associated
morbidities and costs [39]. Furthermore, the majority of
unknown primary tumors are not detected, either due to
insufficient sensitivity of FDG PET/CT or due to disap-
pearance of the primary tumor [12].
Regardless of its ability to detect an unknown primary
tumor, another important aspect of FDG PET/CT that
should be considered is its ability to identify or rule out
additional metastatic sites, which may have important
implications for patient management. This may particularly
be of interest in patients with CUP who present with lymph
node metastatic disease only, because M stage, which has
important therapeutic and prognostic consequences, is still
unknown in these patients. Also, detection of additional
Fig. 4 Bar graph showing
percentages of false-negative
FDG PET/CT results per
location [12]
Fig. 5 Bar graph showing
percentages of false-positive
FDG PET/CT results per
location [12]
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study might help in modifying and planning the radiother-
apy field appropriately, which is the pivotal modality of
therapy in these patients. Furthermore, a baseline FDG
PET/CT may also play a valuable role for treatment
monitoring following therapeutic intervention [40].
Despite the limited evidence regarding its utility, a
multidisciplinary expert panel of oncologists, radiologists,
and nuclear physicians with expertise in PET/CT concluded
that using FDG PET(/CT) in the diagnostic work-up of
patientswithCUPcancerisbeneficial[41]. If FDG PET(/CT)
findings are positive, confirmatory biopsy is necessary
because of the risk of false-positive results [41]. Further-
more, the expert panel recommended that if FDG PET(/CT)
findings are negative in case of a suspected unknown
primary tumor in the head and neck region, further effort
should be made to identify the primary tumor because of the
chance of false-negative results [41]. However, CUP is not
yet among the nine oncology types that are currently
reimbursed by Medicare. Nevertheless, under Medicare’s
Coverage with Evidence Development (CED) policy, FDG
PET(/CT) became a covered service for previously non-
covered cancer indications, including CUP, if prospective
registry data were collected [42]. Recently reported data
from the National Oncologic PET Registry (NOPR) showed
that 1,929 of 22,976 (8.4%) FDG PET(/CT) scans under the
CED policy were performed for diagnosis in patients with
CUP [42]. Although changes in patient management due to
FDG PET(/CT) findings were not reported for CUP
separately, it was stated that FDG PET/CTchanged treatment
decisions in 36.5% of all cases after FDG PET(/CT), while
the impact of FDG PET(/CT) on treatment decisions varied
minimally by the specific cancer indication [42]. In addition,
four individual studies in patients with CUP reported the
therapeutic impact of FDG PET/CT; in these four studies,
FDG PET/CT modified therapy in 18.2–60% of patients
[43–46]. Furthermore, one study [37] reported that median
overall survival between FDG PET/CT-positive and FDG
PET/CT-negative groups was not significantly different,
while another study [20] reported that the survival rate of
CUP patients with at least one hypermetabolic lesion was
significantly lower (p<0.0279) than that of the remaining
CUP patients. However, to the best of our knowledge, no
study has investigated FDG PET/CT-modified patient out-
comes. Therefore, the additional value of FDG PET/CT to
patients with CUP and its cost-effectiveness should be
further investigated.
Challenges and future considerations
Compared to other diagnostic procedures that are often
used in patients with CUP (e.g., CT alone and endoscopic
procedures), FDG PET/CT is both noninvasive and a very
sensitive tomographic whole-body imaging modality,
allowing for the detection of a primary tumor and complete
tumor staging in a single examination. It can be argued that
if FDG PET/CT fails to detect a primary tumor, other
diagnostic procedures are also likely to fail. Therefore,
perhaps FDG PET/CT should be used as a first-line
imaging modality in all patients with metastatic disease
rather than using it after other diagnostic procedures have
failed to identify a primary tumor. This possible beneficial
shift in the diagnostic work-up of patients with metastatic
disease requires further investigation.
In CUP the primary tumor is often of small size [1].
Small tumors with a size around or below the spatial
resolution of a PET system may not be reliably detected
unless intense FDG uptake is present. However, even if
such a small lesion has a high FDG uptake, partial volume
averaging with the surrounding normal tissue may occur,
resulting in a considerable decrease in the qualitatively or
(semi-)quantitatively perceived FDG uptake. Consequently,
the lesion may incorrectly resemble a benign process,
which generally has a lower FDG uptake [standardized
uptake value (SUV)<2.5–3.0] than a malignant lesion [11].
Therefore, technological advances that lead to a higher
signal to noise ratio (SNR) and a higher spatial resolution
are likely to increase the diagnostic yield of FDG PET/CT
in CUP. In this context, the reintroduction of time-of-flight
(TOF) PET may play an important role [10, 47]. PET
systems with TOF capabilities are currently commercially
available for clinical practice [10, 47]. In TOF PET, the
actual time difference in the arrival of the two annihilation
protons at the detectors is recorded [10, 47]. The TOF
information is incorporated directly into the reconstruction
algorithm permitting some combination of faster scanning,
improved SNR, or improved spatial resolution [10, 47].
Another very important issue is the fact that several
tumors exhibit a maximum FDG uptake well beyond 60
min after FDG administration while surrounding normal
tissues show a decline in FDG uptake with time [48–50].
Therefore, lesion-to-background contrast can be consider-
ably increased at delayed PET imaging [48–50], thereby
increasing detectability of the unknown primary tumor. It
should be emphasized that especially in CUP, in which the
primary tumor may be of small size and exhibit low FDG
uptake, any improvement in sensitivity of the technique is
crucial. Thus, it may be recommended to routinely use
delayed PET imaging in this specific patient population. Of
note, to the best of our knowledge, no study has
investigated the promising use of delayed PET imaging in
CUP yet.
Another issue worthy of mention is the use of dynamic
FDG PET studies and PET parametric images which can be
particularly useful for the detection and characterization of
Eur J Nucl Med Mol Imaging (2010) 37:635–644 641small lesions in the oropharynx, lung, liver, or pancreas
[51]. This is presently an area of research and the search is
on by several research centers to define a reliable and
robust parametric imaging algorithm for dynamic PET
studies as well as finding out the correct data reduction
methods that can facilitate interpretation and substantiate
visual analysis of large image sequences and at the same
time can preserve important information [52, 53]. Despite
its quantitative utility, dynamic PET imaging has been
confined primarily to research centers and has not been in
use in a busy clinical setting mainly because it is
technically demanding.
Another promise for the future is the development of
whole-body PET/MRI systems [54]. Although several
technological difficulties have to be solved for designing a
fully integrated whole-body PET/MRI system (including
the issues of electromagnetic interference between the two
systems and MRI-based attenuation correction), and its
high (development) costs have to be taken into account, it
theoretically offers several advantages over a combined
PET/CT system [54], which may also be of interest to
patients with CUP. First, a fully integrated PET/MRI
system allows true simultaneous scanning (instead of
sequential scanning with PET/CT), thereby minimizing
the mismatch between functional (PET) and anatomical
(MRI) data sets [54]. Second, the superior soft tissue
contrast of MRI and the possibility to acquire a variety of
tissue contrasts may improve primary tumor detection and
localization [54]. Especially in several body regions,
including brain, liver, other soft tissue regions, and bone
marrow, MRI may outperform CT [54, 55]. Third, MRI
allows functional tissue information to be obtained, which
may aid in primary tumor detectability. In this respect,
whole-body diffusion-weighted MRI (DWI), a rapidly
evolving functional whole-body technique, may play an
important role [56, 57]. DWI depicts areas with an impeded
diffusion, such as occurs in many malignant tumors.
Similar to FDG PET, DWI offers a high lesion-to-
background contrast, making it a sensitive tool for the
detection of lesions [56, 57]. The utility of whole-body
DWI in patients with CUP was recently reported [58].
Advantages of DWI over FDG PET are its higher spatial
resolution, and its superior ability in evaluating the urinary
tract, where normal FDG accumulation may obscure
lesions. Furthermore, apparent diffusion coefficient (ADC)
measurements (a quantitative measure of diffusion in
biological tissue) may allow characterization of suspicious
lesions [56, 57, 59]. On the other hand, DWI also shows
several normal structures with an impeded diffusion, and
ADC measurements of benign and malignant lesions may
overlap [56, 57, 59]. Thus, both FDG PET and DWI have
their strengths and weaknesses, but a combination of both
modalities may outperform either one of them alone; such a
concept can be realized when PET/MRI systems become
clinically available.
Finally, another promising development is the use of
molecular technology that allows large-scale gene expres-
sion profiling. Several gene expression assays have been
validated using samples from primary tumors or known
metastatic lesions. The application of such a molecular
assay that evaluates the expression of multiple tissue type-
specific gene markers using quantitative reverse transcrip-
tase polymerase chain reaction has shown to be very useful
to predict the origin of the primary tumor in CUP [60, 61].
The combination of molecular technology and advanced
imaging techniques is expected to play an important role in
the diagnostic management of patients with CUP.
Conclusion
In conclusion, an appropriate use and interpretation of FDG
PET/CT is necessary to maximize its diagnostic perfor-
mance in CUP. In the near future, an advanced multi-
parametric approach, including the use of FDG PET/CT or
FDG PET/MRI, functional whole-body MRI techniques,
and molecular technology that allows gene expression
profiling, is expected to outperform the diagnostic yield of
FDG PET/CT alone. Studies investigating the impact of
FDG PET/CT and other advanced diagnostic tests on
therapeutic management, survival, and cost-effectiveness
in CUP are of crucial importance.
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